UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Koninklijke Philips (NYSE:PHG - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 141,259 shares of the technology company's stock, valued at approximately $4,622,000.
Several other institutional investors also recently bought and sold shares of the company. Fairscale Capital LLC bought a new position in shares of Koninklijke Philips in the second quarter worth approximately $54,000. Eastern Bank purchased a new position in Koninklijke Philips in the 3rd quarter worth approximately $88,000. RPg Family Wealth Advisory LLC bought a new position in Koninklijke Philips in the 3rd quarter valued at approximately $107,000. CWM LLC boosted its stake in Koninklijke Philips by 21.9% during the 2nd quarter. CWM LLC now owns 3,429 shares of the technology company's stock valued at $86,000 after purchasing an additional 616 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Koninklijke Philips by 902.7% in the 2nd quarter. Blue Trust Inc. now owns 3,700 shares of the technology company's stock worth $93,000 after purchasing an additional 3,331 shares in the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on PHG shares. StockNews.com downgraded Koninklijke Philips from a "buy" rating to a "hold" rating in a report on Thursday, November 14th. Jefferies Financial Group raised shares of Koninklijke Philips from an "underperform" rating to a "hold" rating in a report on Tuesday, October 29th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold".
Check Out Our Latest Report on PHG
Koninklijke Philips Stock Performance
Shares of PHG stock traded down $0.42 on Thursday, reaching $25.63. The stock had a trading volume of 803,554 shares, compared to its average volume of 946,582. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.74 and a current ratio of 1.16. Koninklijke Philips has a 1 year low of $19.55 and a 1 year high of $32.91. The stock has a market cap of $24.09 billion, a P/E ratio of -61.02, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76. The company has a 50 day simple moving average of $28.39 and a 200 day simple moving average of $28.22.
Koninklijke Philips Profile
(
Free Report)
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Recommended Stories
Before you consider Koninklijke Philips, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Koninklijke Philips wasn't on the list.
While Koninklijke Philips currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.